Computing giant Nvidia has invested $50 million USD in Recursion to fuel the development of its artificial intelligence (AI) drug-discovery technology, as part of a deal that will see the two United States (US) firms collaborate.
The investment comes shortly after Recursion acquired two emerging Canadian AI drug-discovery firms.
Recursion, a Salt Lake City, Utah-based biotech company with a Canadian presence, plans to use this funding to build its AI foundation models for biology and chemistry. The company also intends to distribute these models to other firms with Nvidiaâs BioNeMo platformâa cloud service for generative AI in drug discovery Nvidia announced late last year.
As Nasdaq-listed Recursion looks to do just that, the companyâs chief communications officer Ryan Kelly told BetaKit that the firm expects Canada to play a role.
The Nvidia investment comes shortly after Recursion acquired two emerging Canadian AI drug-discovery companies in Torontoâs Cyclica and MontrĂ©al-based Valence Discovery, and opened a new 28,000-square-foot Canadian headquarters in Toronto.
In May, Recursion announced agreements to buy Cyclica for $40 million and Valence for $47.5 million in stock. Both deals have since closed. According to Recursion, Cyclica and Valence have developed machine learning (ML) methods and models that complement the biotech companyâs existing capabilities.
RELATED: American biotech Recursion acquires two Canadian AI drug-discovery companies Cyclica and Valence
Currently, 100 of Recursionâs 580 employees are based in Canada, which houses the majority of the firmâs ML and engineering teams. Recursionâs Toronto officeâits largest non-US siteâplays home to the firmâs digital chemistry teams following its purchase of Cyclica. Valence, previously located at the Quebec-based AI research institute Mila, is joining forces with Recursionâs deep learning research office in MontrĂ©al, where it will become an AI and ML research centre.
âToronto and MontrĂ©al have long been recognized as centers for cutting-edge technology, biology and chemistry,â said Kelly, who noted that Recursionâs recent acquisitions and new Canadian headquarters reflect its confidence in both the countryâs talent pool and the biotech sectorâs capacity to drive economic growth.
For Nvidia, which makes specialized chips designed to power AI products, the Recursion investment marks the latest in a series of bets on AI for the firm, which have helped fuel a recent surge in its stock price. As interest in AI has heated up, so has interest in Nvidia: in May, the company hit a $1-trillion market valuation, becoming the worldâs first chip maker to do so.
Feature image courtesy Recursion.